Table 2.
Comparison of catheter-related bloodstream infections in Tego and control cohorts
| Control (n=6,493) |
Tego (n=10,652) |
P-value | |
|---|---|---|---|
| IV antibiotic starts | |||
| At-risk time, patient-years | 1,694 | 2,811 | |
| Events | 2,225 | 3,308 | |
| Crude rate (95% CI), events per 100 patient-years | 131 (126–137) | 118 (114–122) | |
| Crude IRR (95% CI) | 1 (ref) | 0.90 (0.85–0.95) | <0.001 |
| Model 1: adjusted IRR (95% CI) | 1 (ref) | 0.92 (0.87–0.97) | 0.002 |
| Model 2: adjusted IRR (95% CI) | 1 (ref) | 0.92 (0.87–0.97) | 0.002 |
| IV antibiotic course (2+ doses within 21-day period) | |||
| At-risk time, patient-years | 1,694 | 2,811 | |
| Events | 1,730 | 2,499 | |
| Crude rate (95% CI), events per 100 patient-years | 102 (97–107) | 89 (85–92) | |
| Crude IRR (95% CI) | 1 (ref) | 0.87 (0.82–0.93) | <0.001 |
| Model 1: adjusted IRR (95% CI) | 1 (ref) | 0.89 (0.84–0.95) | <0.001 |
| Model 2: adjusted IRR (95% CI) | 1 (ref) | 0.89 (0.84–0.95) | <0.001 |
| Positive blood culture | |||
| At-risk time, patient-years | 1,694 | 2,811 | |
| Events | 526 | 828 | |
| Crude rate (95% CI), events per 100 patient-years | 31 (28–34) | 30 (28–32) | |
| Crude IRR (95% CI) | 1 (ref) | 0.95 (0.85–1.06) | 0.34 |
| Model 1: adjusted IRR (95% CI) | 1 (ref) | 0.98 (0.88–1.09) | 0.72 |
| Model 2: adjusted IRR (95% CI) | 1 (ref) | 0.98 (0.88–1.09) | 0.71 |
Notes: Model 1 adjusted for age, race, vintage, and etiology in end-stage renal disease; Model 2 adjusted for all variables (age, sex, race, vintage, primary cause of ESRD, diabetes, heart failure, ischemic disease, cerebrovascular disease, cardiac dysrythmia, COPD, liver disease, malignancy, and Charlson comorbidity index). Tego needlefree connector is manufactured by ICU Medical, Inc., San Clemente, CA, USA.
Abbreviations: CI, confidence interval; IRR, incidence-rate ratio; IV, intravenous; ref, reference.